Onyx Biotec Ltd
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
- Market Cap ₹ 111 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 36.5
- Book Value ₹
- Dividend Yield %
- ROCE 12.0 %
- ROE 14.1 %
- Face Value ₹
Pros
Cons
- Company might be capitalizing the interest cost
- Debtor days have increased from 66.1 to 104 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 39.49 | 39.49 | 53.75 | |
| 34.99 | 34.99 | 45.42 | |
| Operating Profit | 4.50 | 4.50 | 8.33 |
| OPM % | 11.40% | 11.40% | 15.50% |
| 0.11 | 0.11 | 0.13 | |
| Interest | 0.57 | 0.57 | 2.16 |
| Depreciation | 1.49 | 1.49 | 2.25 |
| Profit before tax | 2.55 | 2.55 | 4.05 |
| Tax % | 27.45% | 27.45% | 25.19% |
| 1.84 | 1.84 | 3.03 | |
| EPS in Rs | 3.12 | 3.12 | 2.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 13.32 |
| Reserves | 12.30 | 12.30 | 11.56 |
| 29.23 | 29.23 | 30.78 | |
| 11.30 | 11.30 | 18.47 | |
| Total Liabilities | 58.73 | 58.73 | 74.13 |
| 42.50 | 42.50 | 43.48 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 16.23 | 16.23 | 30.65 | |
| Total Assets | 58.73 | 58.73 | 74.13 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 6.24 | 1.96 | 1.52 | |
| -22.67 | -22.68 | -3.15 | |
| 16.43 | 16.43 | 3.09 | |
| Net Cash Flow | -0.01 | -4.30 | 1.46 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 46.95 | 46.95 | 104.37 |
| Inventory Days | 109.92 | 109.92 | 92.94 |
| Days Payable | 120.16 | 120.16 | 140.83 |
| Cash Conversion Cycle | 36.71 | 36.71 | 56.48 |
| Working Capital Days | 51.39 | 51.39 | 86.11 |
| ROCE % | 6.60% | 12.05% |
Documents
Annual reports
No data available.
Business Overview:[1]
OBL is associated with the healthcare segment and is a supplier of sterile pharmaceutical products to major corporations. Presently, OBL manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. It provides end-to-end product development and manufacturing solutions and its services
also include preparation and filing of regulatory dossiers in the Indian and global markets.